Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

Share Price is delayed by 15 minutes
Get Live Data
34.20    0.90 (2.70%)
Bid:
33.80
Ask:
34.50
Spread: 0.70 (2.071%)
Market Cap: £25.11m
CAR Live PriceLast checked at - London Stock Exchange

Intraday Carclo Share Chart

Trading Update

5 Sep 2024 07:00

RNS Number : 9408C
Carclo plc
05 September 2024
 

05 September 2024

 

 

Carclo plc

 

Trading Update

Carclo plc, the leading global provider of high-precision components, offering comprehensive services from mould design, automation and production to assembly and printing, serving the life sciences, aerospace, optics and tech sectors, provides the following trading update ahead of our AGM.

Financial Performance

Our strategic focus on improving our balance sheet, enhancing asset utilisation, prioritising margin over volume, and maximising our global footprint continues to yield positive results.

The Group's trading performance year to date is in line with management's expectations. The US manufacturing rationalisation and improvement programme is on track. By focussing on cash management and leveraging stronger trading, we have further improved our net debt to uEBITDA ratio. This progress highlights our unwavering commitment to strengthening our financial health across all operations.

Our expectations for the FY25 full year and FY26 remain unchanged with margin expansion anticipated to continue as the Group starts to see the full benefits of the operational optimisation process, continuing our journey toward our strategic goals of 10% return on sales and 25% return on capital employed.

CTP Design & Engineering

Our CTP Design & Engineering division maintains its focus on asset revitalisation projects, which are crucial for driving the next phase of operational improvements. This strategic emphasis underlines our commitment to sustainably enhancing overall company performance and meeting the evolving needs of our clients. These efforts continue to strengthen Carclo's leadership position in the sector, with a clear vision for sustained, medium-term growth.

CTP US Manufacturing Solutions

The restructuring of our US operations is progressing ahead of schedule, as highlighted during our full-year results presentation. We have successfully completed final production runs in Tucson and are now fully focused on our operational turnaround strategy at our centralised facility in Pennsylvania.

New leadership teams in our specialised production cells are beginning to drive important improvements in asset utilisation and operational performance, which are leading to the expected enhancement in margins. These proactive measures position us well to address short-term challenges while keeping our eyes on the medium to long-term strategic goals.

CTP EMEA Manufacturing Solutions

Our CTP EMEA Manufacturing Solutions division continues to build on its strong performance as we focus on the next phase of operational improvement through material and process optimisation. Following the new operational setup in EMEA, the region has emerged even stronger, with lasting enhancements in operational efficiency.

We have achieved an optimal balance of efficiency and flexibility by establishing long-run operations in the UK and medium-flexible runs at our facility in the Czech Republic, which enables us to effectively meet the growing demands of the EMEA market.

Speciality Division

We have now combined our Aerospace and Specialised Optics businesses into our Speciality Division, dedicated to providing customised solutions for niche markets. Both sectors utilise a strong market position built on specialised precision components, ongoing innovation, and exceptional customer support. The Aerospace sector, in particular, has continued its growth trajectory, showcasing the success of our strategic initiatives and commitment to precision leadership. Our expanding precision machining capabilities have enhanced our product offerings, further strengthening Carclo's respected position in the aerospace industry. These accomplishments reflect our steadfast commitment to quality and innovation across all specialty operations.

Further details will be provided in our interim results for the six months ending 30 September 2024, which will be released later this year.

 

LEI: 21380078MEM399JPI956

 

Enquiries:

Carclo plc +44 (0) 20 8685 0500

Frank Doorenbosch Chief Executive Officer

Eric Hutchinson Chief Financial Officer

 

 

Forward-looking statements

 

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and are subject to a number of risks and uncertainties that could cause outcomes to differ materially from those expected.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFFEAFISIIS
Date   Source Headline
12th Jul 201811:25 amBUSForm 8.3 - Carclo plc - Ordinary shares
12th Jul 201811:00 amRNSForm 8.3 - Carclo plc
11th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
11th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
10th Jul 20185:50 pmRNSForm 8.3 - [Carclo plc]
10th Jul 20185:27 pmRNSForm 8.3 - [Carclo plc]
10th Jul 20184:10 pmRNSForm 8.3 - [carclo plc]
10th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
10th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
10th Jul 20189:57 amBUSForm 8.3 - Carclo PLC
9th Jul 20183:55 pmRNSForm 8.3 - Carclo plc
9th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
9th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
9th Jul 201810:39 amRNSForm 8.3 - Carclo plc
6th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
6th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
5th Jul 201812:09 pmRNSForm 8 (OPD) - CONSORT MEDICAL PLC
5th Jul 201812:08 pmRNSForm 8 (OPD) - Carclo plc
5th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
4th Jul 20183:04 pmRNSHolding(s) in Company
4th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
4th Jul 201810:26 amRNSForm 8.3 - Carclo plc
3rd Jul 20184:22 pmRNSForm 8.3 - Carclo Plc
3rd Jul 20182:33 pmPRNForm 8.3 - Carclo plc
3rd Jul 20182:26 pmRNSForm 8.3 - [Carclo plc]
3rd Jul 20181:56 pmRNSForm 8.3 - Carclo Plc
3rd Jul 20181:49 pmRNSHolding(s) in Company
3rd Jul 20181:32 pmRNSForm 8.3 - Carclo plc
3rd Jul 20181:00 pmRNSForm 8.3 - Carclo plc
3rd Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
3rd Jul 201811:36 amBUSForm 8.3 - Carclo plc - Ordinary shares
3rd Jul 201811:07 amRNSForm 8.3 - [Carclo plc]
2nd Jul 20181:07 pmRNSResponse to announcement from Consort Medical
2nd Jul 20187:00 amRNSNon-Binding Proposal for Carclo plc
28th Jun 20187:00 amRNSBoard changes
6th Jun 201810:27 amRNSHolding(s) in Company
5th Jun 20187:00 amRNSFinal Results
17th Apr 20187:00 amRNSDirectorate Change
9th Apr 20188:25 amRNSYear End Trading Update
26th Jan 20185:25 pmRNSDirector/PDMR Shareholding
24th Jan 201812:43 pmRNSDirector/PDMR Shareholding (Replacement)
24th Jan 201810:12 amRNSDirector/PDMR Shareholding
17th Jan 201811:27 amRNSHolding(s) in Company
16th Jan 201811:44 amRNSHolding(s) in Company
15th Jan 20187:00 amRNSTrading Update and Board Changes
12th Jan 20182:55 pmRNSHolding(s) in Company
12th Jan 20181:45 pmRNSHolding(s) in Company
10th Jan 20185:01 pmRNSHolding(s) in Company
28th Nov 20175:30 pmRNSHolding(s) in Company
14th Nov 20177:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.